Test test test
bla bla bla! Read more
bla bla bla! Read more
Hello! Another post to test! Read more
Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Hello MarkLogic! This is a test! Read more
In a tongue-in-cheek contest of microscopic mobility, a line of bone marrow stem cells from Singapore beat out dozens of competitors to claim the title of the world’s fastest cells.
The millions of monarchs (Danaus plexippus) that flit on fragile wings from the United States to a particular area of fir forest in Mexico—as far as 4,000 kilometres—are making the journey for the first time. Read more
A diagnosis of amyotrophic lateral sclerosis (ALS) is considered a life sentence. Most people with the neurodegenerative disease, which attacks the neurons responsible for motor control, only survive two or three years after their diagnosis — and 5,000 such diagnoses are made each year in the United States alone. Despite the need, however, there is only a single drug on the market that targets ALS: Rilutek (riluzole), made by France’s Sanofi. But this agent only prolongs life by two or three months on average. Recent advances provide some hope for future drug pathways that can be targeted to treat the disease.
Recent comments on this blog
delayed 12:25
delayed 12:25
delayed 12:25
Test ingestion 05 09 2012
Test ingestion 05 09 2012